High frequency of drug-resistant mutation to nucleos(t)de analogues in hepatitis B virus (HBV) infected people living with HIV, in the Northeast region of Colombia.
The present poster summarizing significant findings related to Hepatitis B virus (HBV) antiviral resistance-associated mutations (RAMs) in individuals coinfected with human immunodeficiency virus (HIV) who were undergoing highly active antiretroviral therapy (HAART). The study aimed to investigate the prevalence of HBV coinfection, HBV genotypes, and the presence of RAMs in a cohort of people living with HIV (PLWH) in the northeastern region of Colombia. Between February 2013 and February 2014, a cross-sectional study was conducted, collecting virological, immunological, and HAART data from clinical records. In-house nested PCR and Sanger sequencing were used to identify coinfections, genotypes, RAMs, and HBV surface antigen (HBsAg) escape mutants. Key findings include the confirmation of HBV coinfection in 11.6% of the 275 PLWH, with a breakdown of 28.2% having active hepatitis B (HBsAg positive) and 71.8% having occult hepatitis B infections (OBI). All HBV sequences (n = 23) belonged to genotype F3. Notably, most patients coinfected with HIV/HBV had CD4+ T cell counts above 200 cells/mm³, and 37.5% had undetectable HIV viral loads. RAMs associated with resistance to lamivudine/telbivudine and partial resistance to entecavir were present in all HBV isolates. Additionally, an unidentified rt236Y mutation related to tenofovir resistance was identified. ADAPVEMs in the S gene were observed in all isolates, although no vaccine escape mutants were detected. In conclusion, the study underscores the significance of HBV molecular screening, resistance monitoring, and the development of new guidelines for PLWH to address RAMs and mitigate HBV-related liver diseases.
Steps to reproduce
This cross-sectional study was carried out between February 2013 and February 2014. Virological, immunological and highly active antiretroviral therapy (HAART) data were collected from clinical records. In-house nested PCR and Sanger sequencing of the HBV pol gene were used to identify coinfections, genotypes, RAMs and HBV s antigen (HBsAg) escape mutants.